Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Artemis US Select Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Artemis US Select Fund strongly outperformed its benchmark in Q4 2025 with a 7.0% gain. Managers are actively rotating capital from industrials and staples into healthcare and semiconductor names, preparing for a rate-cut driven recovery and wider dispersion in AI stocks in 2026."
Artemis US Select Fund reported a 7.0% return in Q4 2025, outperforming its benchmarks (S&P 500 at 2.7% and IA North America sector average at 2.4%). For the full year 2025, the fund returned 10.0% compared to 9.6% for the S&P 500. Major positive contributors included AMD, Cardinal, Micron, Parker Hannifin, and Eli Lilly, while Axon, Royal Caribbean, Live Nation, and Corteva acted as detractors. During the quarter, the fund executed substantial portfolio changes, entirely exiting positions in Coca-Cola, Eaton, Western Digital, and Corteva, while opening new positions in IQVIA and Applied Materials, and increasing exposure to Eli Lilly and nVent Electric. The manager's outlook for 2026 focuses on monetary easing, deregulation, M&A revival, healthcare sector recovery, and the increasing dispersion of the AI-driven market.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Artemis US Select Fund strongly outperformed its benchmark in Q4 2025 with a 7.0% gain. Managers are actively rotating capital from industrials and staples into healthcare and semi...
Growth Outlook
Market outlook remains above average conviction: Artemis US Select Fund strongly outperformed its benchmark in Q4 2025 with a 7.0% gain. Managers are actively rotating capital from industrials and staples into healthcare and semi...
Risk Appetite
Risk appetite posture is above average conviction: Artemis US Select Fund strongly outperformed its benchmark in Q4 2025 with a 7.0% gain. Managers are actively rotating capital from industrials and staples into healthcare and semi...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Artemis US Select Fund strongly outperformed its benchmark in Q4 2025 with a 7.0% gain. Managers are actively rotating capital from industrials and staples into healthcare and semi...
Forward Guidance
Forward guidance signal: Artemis US Select Fund strongly outperformed its benchmark in Q4 2025 with a 7.0% gain. Managers are actively rotating capital from industrials and staples into healthcare and semi...
Language Signal
Tone analysis indicates above average conviction language: Artemis US Select Fund strongly outperformed its benchmark in Q4 2025 with a 7.0% gain. Managers are actively rotating capital from industrials and staples into healthcare and semi...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Artemis US Select Fund strongly outperformed its benchmark in Q4 2025 with a 7.0% gain. Managers are actively rotating capital from industrials and staples into healthcare and semi...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. Artemis US Select Fund strongly outperformed its benchmark in Q4 2025 with a 7.0% gain. Managers are actively rotating capital from industrials and staples into healthcare and semi...
Time Horizon
Investment time horizon reflects a high conviction orientation. Artemis US Select Fund strongly outperformed its benchmark in Q4 2025 with a 7.0% gain. Managers are actively rotating capital from industrials and staples into healthcare and semi...
